Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CeNeRx BioPharma Inc.

www.cenerx.com

Latest From Calistoga Pharmaceuticals Inc.

TG Therapeutics Builds A Business Model For Today

The speed with which TG Therapeutics burst on the scene, along with the impressive potency and safety of its novel combinations of cancer drugs, has perhaps blinded observers to the unique business model that has carried it this far.

BioPharmaceutical Strategy

Frazier capitalizes on Calistoga, recruits former CEO Gallagher to the VC firm

Two and a half years after Calistoga Pharmaceuticals was acquired by Gilead Sciences for up to $600m, Frazier Healthcare finally lured Calistoga's former CEO Carol Gallagher to help the venture capital firm replicate its successful investment in the cancer drug developer.

Cancer

Deals of the Week: IPO Window Raises Stakes For M&A

Rather than continue down the path to a public offering, Aragon sells to J&J for a hefty price. Also, MedImmune strikes a diabetes and obesity deal with NGM, Teva buys respiratory drug maker MicroDose, and Sanofi allies with the Curie Institute to study ovarian cancer.

BioPharmaceutical United States

A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million

Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CeNeRx BioPharma Inc.
  • Senior Management
  • Barry Brand, CEO
    Dan Burch, MD, EVP, R&D & CMO
  • Contact Info
  • CeNeRx BioPharma Inc.
    Phone: (919) 234-4072
    270 Cornerstone Dr.
    Ste. 103
    Cary, NC 27519
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register